Genome Instability & Disease (GIAD) publishes high-quality, peer-reviewed original research papers, short communications, and review articles on the molecular mechanisms underlying genome stability maintenance and genome instability-associated human diseases and therapeutic applications. In particular, GIAD publishes novel data regarding the regulatory mechanisms of genome stability, including epigenetic and post-translational modifications, and the DNA damage response and its association with the inheritance of mutations that contribute to genetic disorders, neurodegenerative diseases, cancer, and ageing.

Topics may include, but are not limited to:

§ Cell cycle checkpoints

§ DNA damage response

§ Post-translational modifications

§ Epigenetic regulation

§ Radio/chemotherapeutic sensitization

§ Genome stability genes as a therapeutic target

§ Genome instability-associated diseases

§ Neurodegenerative diseases

§ DNA damage-based therapy and drug discovery

GIAD publishes one volume per year, consisting of six regular issues. All submissions undergo a double-blind peer review process.

The journal will be officially launched in January 2020 but submissions are very much welcomed from now on. The accepted articles will be published as online first before January 2020.

Journal information

  • Wei-Guo Zhu,
  • Marco Foiani
Publishing model
Hybrid. Open Access options available

Latest articles

You have access to our articles


Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access
  • Full Journal access includes all articles
  • Downloadable in PDF
  • Subscription expires 12/31/2020


About this journal

Electronic ISSN
Abstracted and indexed in
  1. EBSCO Discovery Service
  2. Google Scholar
  3. Institute of Scientific and Technical Information of China
  4. Naver
  5. OCLC WorldCat Discovery Service
  6. ProQuest-ExLibris Primo
  7. ProQuest-ExLibris Summon
Copyright information

Rights and permissions

Springer Nature policies

© Shenzhen University School of Medicine; Fondazione Istituto FIRC di Oncologia Molecolare